

PROSTATE ALL-INCLUSIVE ASSAY


超微攝護腺前兆精測

Benign Prostatic Hyperplasia & Prostate Cancer

良性前列腺增生 & 前列腺癌 (報告範本)

Patient:	Hospital:
Age: 歲	Treating Physician:
Sex: Male	Specimen ID:
Order Received: 2023//	Sampling Date: 2023//
Lab Requisition #: PAI#	
Specimen Type: Urine Exosome DNA	
Date Reported:	
Clinical Indication:	

TEST RESULTS: RISK SCORE (風險評分)



INDEX 指數	ITEM 項目	BIOMARKER 生物標記	RISK SCORE 風險評分
PSI	Benign Prostatic Hyperplasia 良性前列腺增生	PAGE4*	45
PMI	Prostate Cancer 前列腺癌	CYCLIN D1/p16	0
PSA	Prostatitis 前列腺炎	PSA	30

Score Range: 0–100

0: No Risk 無風險


1-35: Low Risk 低風險

36- 75: Intermediate Risk 中度風險

76- 100: High 高風險

BPH RISK ASSESSMENT(良性前列腺增生)

Prostate Swelling Index (PSI 前列腺腫脹指數)



0-35%: Low Risk; 36-75%: Mid Risk; 76-100%: High Risk


BIOMARKER 生物標記	RISK LEVEL 風險等級		DIAGNOSIS 診斷結果
PAGE4*	++		INTERMEDIATE STAGE OF BPH 良性前列腺增生 中期
ATTRIBUTE 屬性	Anti-apoptosis 抗細胞凋亡	Stress-responsive 壓力回應	

INTERPRETATION

MID-STAGE OF BENIGN PROSTATIC HYPERPLASIA 良性前列腺增生中期

PROSTATE CANCER RISK ASSESSMENT(前列腺癌風險評估)

Prostate Malignancy Index (PMI 前列腺惡性腫瘤指數)



0-35%: Low Risk; 36-75%: Mid Risk; 76-100%: High Risk


BIOMARKER 生物標記	RISK LEVEL 風險等級		DIAGNOSIS 診斷結果
	PREMALIGNANCY 癌前病變	MALIGNANCY 惡性腫瘤	
CYCLIN D1	-	N/A	NO RISK FOR PROSTATE CANCER 無前列腺癌風險
CDKN2A	N/A	-	
ATTRIBUTE 屬性	Prostatic intraepithelial neoplasia (PIN) 前列腺上皮內瘤變	Acinar or ductal adenocarcinoma 腺泡或導管腺癌	

INTERPRETATION

NO RISK FOR PROSTATE CANCER 無患前列腺癌的風險

PROSTATITIS RISK ASSESSMENT

前列腺炎風險評估



Prostate Surface Antigen (前列腺表面抗原)

0-35%: Low Risk; 36-75%: Mid Risk; 76-100%: High Risk

BIOMARKER 生物標記	RISK LEVEL 風險等級		DIAGNOSIS 診斷結果
PSA	+		LOW RISK 低風險
ATTRIBUTE 屬性	Prostate secretion 前列腺分泌	Elevated in prostate infection/prostatitis 前列腺感染 / 前列腺 炎升高中	

INTERPRETATION

LOW RISK FOR CHRONIC PROSTATE INFLAMMATION 慢性前列腺炎低風險
--

COMMENTS

PAI Assay is a molecular prostate functional test and can be used as a first-line screening for prostate health conditions. The test is intended to be an ancillary test and should be used in conjunction with other clinical diagnostic procedures for any medical decisions. Like other laboratory tests, PAI Assay must be ordered by an authorized healthcare provider.

PAI 檢測是一種分子前列腺功能測試，可用作前列腺健康情況的一線篩查。該測試旨在作為輔助測試，應與其他臨床診斷程序結合使用，以做出任何醫療決策。與其他實驗室測試一樣，PAI 檢測必須由授權的醫療保健提供者訂購。

*Summary for PAGE4 Gene

This gene is a member of the GAGE family. The GAGE genes are expressed in a variety of tumors and in some fetal and reproductive tissues. This gene is strongly expressed in prostate and prostate cancer. It is also expressed in other male and female reproductive tissues including testis, fallopian tube, uterus, and placenta, as well as in testicular cancer and uterine cancer. The protein encoded by this gene shares sequence similarity with other GAGE/PAGE proteins, and also belongs to a family of CT (cancer-testis) antigens. The protein may play a role in benign and malignant prostate diseases. A related pseudogene is located on chromosome 7. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]

* PAGE4 基因摘要

該基因是 GAGE 家族的成員。GAGE 基因在多種腫瘤以及一些胎兒和生殖組織中表達。該基因在前列腺和前列腺癌中強烈表達。它也在其他男性和女性生殖組織中表達，包括睪丸、輸卵管、子宮和胎盤，以及睪丸癌和子宮癌。該基因編碼的蛋白質與其他 GAGE/PAGE 蛋白具有序列相似性，也屬於 CT（癌症睪丸）抗原家族。該蛋白可能在良性和惡性前列腺疾病中發揮作用。一個相關的假基因位於 7 號染色體上。交替剪接導致多個轉錄本變體。[由 RefSeq 提供，2016 年 1 月]

**Deviations from the “Sample Collection Procedure” recommended for the PAI Assay may compromise the assay accuracy.

**偏離 PAI 檢測推薦的“樣本採集程式”可能會影響檢測的準確性。

Sign: BING LING, MD

Date: 2023//

REFERENCE

- Gervaise H. Henry, Alicia Malewska, Diya B. Joseph, Ryan C. Hutchinson, Chad M. Vezina, Douglas W. Strand, A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra. Cell Reports 25, 3530–3542, December 18, 2018

2. Abdulahi Zubair, Samuel Davis, Damilola I. Balogun, Emeka Nwokeocha, Chineme-anyaeze Chiedoie, Damilola Jesuyajolu. A Scoping Review of the Management of Benign Prostate Hyperplasia in Africa. (November 05, 2022) *Cureus* 14(11): e31135. DOI 10.7759/cureus.31135
3. Hyungseok Cho a, *, Cheol Kyu Oh b, *, Jiwon Cha a, Jae Il Chung c, Seok-Soo Byun d, Sung Kyu Hong d, Jae-Seung Chung b, *, Ki-Ho Han a, **
Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer. p2287-8882 e2287-903X/© 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
4. Dmitri Pchejetski,*, Ewan Hunter, Mehrnoush Dezfouli, Matthew Salter, Ryan Powell, Jayne Green, Tarun Naithani, Christina Koutsothanasi, Heba Alshaker, Jiten Jaipuria, Martin J. Connor, David Eldred-Evans, Francesca Fiorentino, Hashim Ahmed, Alexandre Akoulitchev and Mathias Winkler*. Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. *Cancers* 2023, 15, 821. <https://doi.org/10.3390/cancers15030821>
5. Myong Kim¹, Abhilash Cheeti², Changwon Yoo³, Minsoo Choo¹, Jae-Seung Paick¹, Seung-June Oh¹.*. Non-Invasive Clinical Parameters for the Prediction of Urodynamic Bladder Outlet Obstruction: Analysis Using Causal Bayesian Networks
PLOS ONE | www.plosone.org. November 2014 | Volume 9 | Issue 11 | e113131
6. Keong Tatt Foo, Pathophysiology of clinical benign prostatic hyperplasia. 2214-3882/a 2017 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
7. Stanley A Brosman, MD; Chief Editor: Edward David Kim, MD, FACS more.
Precancerous Lesions of the Prostate. Overview, PIN and ASAP Rates, Diagnostic Significance. Updated: Nov 01, 2022
8. Mark J. Speakman *Taunton & Somerset NHS Trust, Urology, Musgrove Park, Taunton, Somerset TA3 7JS, United Kingdom. Prostate-Specific Antigen: Could It Be a Useful Marker for Bladder Outlet Obstruction? *European urology* 54 (2008) 1223–1225. referring to the article published on pp. 1385–1392 of this issue
9. Filippo Pederzoli ^{1,5}✉, Massimiliano Raffo^{1,2,5}, Hubert Pakula¹, Francesco Ravera^{1,3}, Pier Vitale Nuzzo¹ and Massimo Loda ^{1,4}. “Stromal cells in prostate cancer pathobiology: friends or foes?” Received: 11 October 2022 Revised: 16 November 2022 Accepted: 18 November 2022, *British Journal of Cancer*
10. S-C Hung^{1,2}, S-W Lai^{3,4}, P-Y Tsai^{2,5}, P-C Chen^{2,3}, H-C Wu^{3,6}, W-H Lin⁷ and F-C Sung^{*,2,5}. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk, Received 18 December 2012; revised 14 March 2013; accepted 1 April 2013; published online 23 April 2013 & 2013 *Cancer Research UK*.
11. Yan Li, Jianmin Liu, Daoquan Liu, Zhen Wang, Yongying Zhou, Shu Yang, Feng Guo, Liang Yang, and Xinhua Zhang. The Prostate-Associated Gene 4 (PAGE4) Could Play a Role in the Development of Benign Prostatic Hyperplasia under Oxidative Stress. *Oxidative Medicine and Cellular Longevity* Volume 2022, Article ID 7041739, 22 pages
12. ABRAHAMSSON, Per-Anders; KURIYAMA, Manabu. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH. *Acta Urol. Jpn.* 44: 223-232, 1998